1Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts. 2Department of Medicine, Harvard Medical School, Boston, Massachusetts. 3Broad Institute of MIT and Harvard, Cambridge, ...
1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
1Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 2Center for Human Immunobiology, Department of Medicine, Feinberg ...
Cancer Res (2025) 85 (18_Supplement_3): B004.
2Department of Surgery, The University of Michigan Medical School, Ann Arbor, Michigan. 3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan. 4Department of Cell and Developmental Biology ...
1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2The Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University ...
BIK Therapeutics Inc., Seongnam, Republic of Korea.
Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...
Search for other works by this author on: ...
Creighton University School of Medicine, Omaha, NE.
Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York ...
University of Arkansas for Medical Sciences, Little Rock, AR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback